Table 2.

Analyses of MT in hematological malignancies

Type of diseases	Number of patients analyzed	Results of the analysis	Ref.
ALL	119 (initial: n = 92, relapsed: n = 27)	Tendency in initial ALL with MT expression, the lower probability of disease free survival. However, no differences concerning MT percentage of positivity and intensity of staining in children with either initial or relapsed ALL. MT expression is not an important prognostic factor in the clinical drug resistance of childhood ALL.	[73]
ALL	47	After chemotherapy, MT positive cases (n = 18) showed maximal effect on the second day of treatment and apoptotic action completed on the tenth day. MT negative cases showed maximal effect on the first day of treatment and completed on the sixth day.	[23]
ALL	60	From microarray CGH analysis, BAK, CDKN2C, GSTM1 and MT-IF as a gene set that differed between ALL patients at diagnosis who had a risk or relapse from those who did not.	[24]
AML	19	The expression of resistance-related proteins P-170, GST-pi, Topo II, TS and MT was investigated. Patients who developed a relapse expressed more than two resistance mechanisms significantly more often than patients who remained remission (p = 0.005). The higher the number of resistance-related proteins in childhood AML the poorer the prognosis of the patients.	[25]
AML	43	mRNA expressions of the MT-IA, G and PU.1 genes were significantly, inversely correlated (MT-IG: R = −0.50, p < 0.001; MT-IA: R = −0.58, p < 0.0005).	[26]
HL	35	MT is differentially expressed in subclassified Hodgkin lymphoma. The number of MT-I, II immunostained cells is significantly higher in MCHL relative to other subclassified HL groups (p < 0.001), and also, the number of these cells is significantly higher in NSHL relative to NLPHL and LRCHL (p < 0.005).	[29]
DLBCL	115	MT labeling of more than 20% lymphoma cells was associated with a significantly poorer 5-year survival, independent of age, stage, or international prognostic index.	[27]
MPD	OMF (n = 9), CML (n = 11)	Increased GST-pi and MT expression in the bone marrow of MPD patients. Levels of MT in OMF patients were higher than in CML.	[28]